G
Gregory A. Daniels
Researcher at University of California, San Diego
Publications - 140
Citations - 10028
Gregory A. Daniels is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Pembrolizumab. The author has an hindex of 35, co-authored 130 publications receiving 7561 citations. Previous affiliations of Gregory A. Daniels include Mayo Clinic & University of California.
Papers
More filters
Journal ArticleDOI
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka,Howard L. Kaufman,Frances A. Collichio,Thomas Amatruda,Neil Senzer,Jason Chesney,Keith A. Delman,Lynn E. Spitler,Igor Puzanov,Sanjiv S. Agarwala,Mohammed M. Milhem,Lee D. Cranmer,Brendan D. Curti,Karl D. Lewis,Merrick I. Ross,Troy H. Guthrie,Gerald P. Linette,Gregory A. Daniels,Kevin J. Harrington,Mark R. Middleton,Wilson H. Miller,Jonathan S. Zager,Yining Ye,Bin Yao,Ai Li,Susan Doleman,Ari M. Vanderwalde,Jennifer Gansert,Robert Coffin +28 more
TL;DR: T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial and represents a novel potential therapy for patients with metastatic melanoma.
Journal ArticleDOI
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M. Goodman,Shumei Kato,Lyudmila Bazhenova,Sandip Pravin Patel,Garrett M. Frampton,Vincent A. Miller,Philip J. Stephens,Gregory A. Daniels,Razelle Kurzrock +8 more
TL;DR: Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse cancers treated with various immunotherapies, and Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.
Journal ArticleDOI
Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells
Daniel Ramsköld,Shujun Luo,Yu-Chieh Wang,Robin Li,Qiaolin Deng,Omid R. Faridani,Gregory A. Daniels,Irina Khrebtukova,Jeanne F. Loring,Louise C. Laurent,Gary P. Schroth,Rickard Sandberg,Rickard Sandberg +12 more
TL;DR: Applying Smart-Seq to circulating tumor cells from melanomas, it is found that although gene expression estimates from single cells have increased noise, hundreds of differentially expressed genes could be identified using few cells per cell type.
Journal ArticleDOI
Cutaneous melanoma, version 2.2019
Daniel G. Coit,John A. Thompson,Mark R. Albertini,Christopher A. Barker,William E. Carson,Carlo M. Contreras,Gregory A. Daniels,Dominick J. DiMaio,Ryan C. Fields,Martin D. Fleming,Morganna Freeman,Anjela Galan,Brian R. Gastman,Valerie Guild,Douglas B. Johnson,Richard W. Joseph,Julie R. Lange,Sameer K. Nath,Anthony J. Olszanski,Patrick A. Ott,Aparna Priyanath Gupta,Merrick I. Ross,April K.S. Salama,Joseph J. Skitzki,Jeffrey A. Sosman,Susan M. Swetter,Kenneth K. Tanabe,Evan Wuthrick,Nicole R. McMillian,Anita M. Engh +29 more
TL;DR: The data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease are summarized.
Journal ArticleDOI
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Michael R. Migden,Nikhil I. Khushalani,Anne Lynn S. Chang,Karl D. Lewis,Chrysalyne D. Schmults,Leonel Hernandez-Aya,Friedegund Meier,Dirk Schadendorf,Alexander Guminski,Axel Hauschild,Deborah J. Wong,Gregory A. Daniels,Carola Berking,Vladimir Jankovic,Elizabeth Stankevich,Jocelyn Booth,Siyu Li,David M. Weinreich,George D. Yancopoulos,Israel Lowy,Matthew G. Fury,Danny Rischin +21 more
TL;DR: Cemiplimab showed antitumour activity and an acceptable safety profile in patients with locally advanced cutaneous squamous cell carcinoma for whom there was no widely accepted standard of care.